Table 3.
Changes in incidence density and final impact.
| Antimicrobial Resistance | ID Pre-Intervention Period | Relative Change Second Semester 2017 |
Relative Change Second Semester 2019 |
Relative Change First Semester 2022 |
Absolute Effect Post-Intervention Period | Relative Preventable Effect (%) |
|---|---|---|---|---|---|---|
| E. Coli | ||||||
| ESBL-producing | 0.370 (0.369 to 0.371) |
0.762 (0.757 to 0.768) |
0.656 (0.652 to 0.662) |
0.556 (0.552 to 0.560) |
−0.115 (−0.116 to −0.114) |
31.01 (31.22 to 30.80) |
| Ciprofloxacin | 1.445 (1.443 to 1.447) |
0.808 (0.805 to 0.810) |
0.513 (0.511 to 0.515) |
0.406 (0.404 to 0.407) |
−0.595 (−0.596 to −0.593) |
41.20 (41.29 to 41.10) |
| Co-amoxiclav | 0.583 (0.582 to 0.585) |
1.186 (1.181 to 1.191) |
0.783 (0.779 to 0.787) |
0.789 (0.785 to 0.793) |
−0.102 (−0.103 to −0.101) |
17.46 (17.65 to 17.26) |
| K. pneumoniae | ||||||
| ESBL-producing | 0.067 (0.067 to 0.067) |
1.326 (1.310 to 1.343) |
1.614 (1.595 to 1.632) |
0.937 (0.923 to 0.950) |
0.018 (0.017 to 0.018) |
20.84 (20.34 to 21.35) |
| Ciprofloxacin | 0.104 (0.104 to 0.105) |
1.080 (1.069 to 1.092) |
1.458 (1.445 to 1.472) |
0.712 (0.702 to 0.721) |
0.013 (0.012 to 0.014) |
11.13 (10.67 to 11.59) |
| Co-amoxiclav | 0.081 (0.080 to 0.081) |
1.437 (1.422 to 1.453) |
1.490 (1.474 to 1.506) |
0.887 (0.875 to 0.899) |
0.027 (0.026 to 0.027) |
24.81 (24.38 to 25.25) |
ID; incidence density per 1000 inhabitants per day expressed with 95% CIs, unless otherwise specified. ESBL; extended-spectrum β-lactamase. Co-amoxiclav; amoxicillin–clavulanic acid.